Enzo Biochem Gross Profit 2010-2022 | ENZ

Enzo Biochem gross profit from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Enzo Biochem Annual Gross Profit
(Millions of US $)
2022 $42
2021 $54
2020 $24
2019 $23
2018 $41
2017 $46
2016 $46
2015 $43
2014 $42
2013 $39
2012 $47
2011 $48
2010 $45
2009 $37
Enzo Biochem Quarterly Gross Profit
(Millions of US $)
2022-07-31 $4
2022-04-30 $10
2022-01-31 $16
2021-10-31 $11
2021-07-31 $10
2021-04-30 $16
2021-01-31 $16
2020-10-31 $12
2020-07-31 $8
2020-04-30 $4
2020-01-31 $6
2019-10-31 $6
2019-07-31 $6
2019-04-30 $5
2019-01-31 $5
2018-10-31 $7
2018-07-31 $8
2018-04-30 $11
2018-01-31 $11
2017-10-31 $11
2017-07-31 $10
2017-04-30 $12
2017-01-31 $12
2016-10-31 $12
2016-07-31 $12
2016-04-30 $11
2016-01-31 $11
2015-10-31 $11
2015-07-31 $11
2015-04-30 $10
2015-01-31 $10
2014-10-31 $11
2014-07-31 $11
2014-04-30 $10
2014-01-31 $10
2013-10-31 $11
2013-07-31 $9
2013-04-30 $9
2013-01-31 $9
2012-10-31 $12
2012-07-31 $12
2012-04-30 $12
2012-01-31 $12
2011-10-31 $12
2011-07-31 $12
2011-04-30 $12
2011-01-31 $10
2010-10-31 $13
2010-07-31 $10
2010-04-30 $11
2010-01-31 $11
2009-10-31 $13
2009-07-31 $11
2009-04-30 $10
2009-01-31 $8
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.087B $0.107B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $169.923B 10.37
GSK (GSK) United Kingdom $77.117B 9.67
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.058B 18.88
Ginkgo Bioworks Holdings (DNA) United States $3.317B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $2.305B 34.61
Biohaven (BHVN) United States $1.089B 0.00
Emergent Biosolutions (EBS) United States $0.608B 4.78
Zymeworks (ZYME) Canada $0.443B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.262B 0.00
SQZ Biotechnologies (SQZ) United States $0.038B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00